Health
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) at the 18th Clinical Trials in Alzheimer's Disease (CTAD) conference, held in San Diego December 1-4. Data suggests potential to delay disease progression from Mild cognitive impairment (MCI) to moderate Alzheimer's disease (AD) by up to 8.3 years in the low-amyloid group who started treatment at an early stage.
About this update from Eisai Co., Ltd.
[{"type":"text","content":"STOCKHOLM, Dec. 4, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) at the 18th Clinical Trials in Alzheimer's Disease (CTAD) conference, held in San Diego December 1-4. Data suggests potential to delay disease progression from Mild cognitive impairment (MCI) to moderate Alzheimer's disease (AD) by up to 8.3 years in the low-amyloid group who started treatment at an early stage. ","length":528,"tagName":"p"},{"type":"text","content":"Additionally, a scientific symposium was held on the subcutaneous formulation with an autoinjector (SC-AI), which was approved for maintenance treatment in the United States in August 2025, and the rolling supplemental Biologics License Application (sBLA) for initiation treatment was completed in November 2025. The application for a subcutaneous injectable formulation in Japan was submitted in November 2025.","length":411,"tagName":"p"},{"type":"text","content":"Real-world data from different clinics and countries were also presented at the congress, demonstrating continued clinical benefit with lecanemab treatment and a safety profile consistent with the phase 3 Clarity AD study.","length":222,"tagName":"p"},{"type":"text","content":"The presentations in summary:","length":29,"tagName":"p"},{"type":"text","content":"Estimating the 10-year time-savings benefits of lecanemab treatment (Presentation: December 3)","length":94,"tagName":"p"},{"type":"text","content":"Based on data from the Clarity AD open-label extension (OLE) and 16 clinical studies of monoclonal antibodies for Alzheimer's disease (AD), this analysis estimated long-term disease progression over 10 years and the slowing effect of continued lecanemab treatment. The analysis evaluated estimated "time savings" (slowing of disease progression) compared to natural decline based on ADNI[1] (Alzheimer's Disease Neuroimaging Initiative) data (untreated group), using Clinical Dementia Rating - Sum of Boxes (CDR-SB). These results suggest that early initiation and long-term lecanemab treatment may continue to slow AD progression and help maintain cognitive function over a longer period.","length":707,"tagName":"p"},{"type":"text","content":"Findings from each group:","length":25,"tagN...